On July 8, 2019 ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine and Ayala Pharmaceuticals, a clinical stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers, reported a strategic collaboration to develop companion diagnostic (CDx) tests targeting cancers bearing Notch activating mutations and fusions (Press release, ArcherDX, JUL 8, 2019, View Source [SID1234537393]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As we continue our work to bring pan-Notch inhibitors to those living with cancers bearing Notch-activating mutations and fusions, we are excited to enter into this collaboration with ArcherDX, a leader in molecular technology," said Roni Mamluk, Ph.D., Chief Executive Officer at Ayala Pharmaceuticals. "We believe that through this partnership we’ll have additional tools to identify those patients most likely to respond to the Notch inhibitors that Ayala is developing."
"Working closely with biopharma partners to help bring biomarker-driven therapies to individuals diagnosed with cancer is central to our mission to improve access to genomic-based medicine. Partnerships with progressive companies such as Ayala who can leverage our unique ability to provide companion diagnostic solutions from both tissue and blood-based specimens and deploy them at scale as in-vitro diagnostics to laboratories around the world is essential to achieving this mission," said Jason Myers, Co-Founder and Chief Executive Officer of ArcherDX. "We’re proud to support Ayala in their pursuit of meaningful new precision oncology treatment options."